A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome

Clinical trial NCT07695298 · RECRUITING

Trial details

NCT number: NCT07695298
Sponsor: Cincinnati Eye Institute, Southwest Ohio
Status: RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Presumed Ocular Histoplasmosis

Start date: 2026-07-01
Primary completion: 2028-05-01
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.